Latest Breaking News On - Regulatory affairs of purple biotech - Page 1 : comparemela.com

Part 2 is a Dose Escalation Study of NT219, in Combination with cetuximab (ERBITUX®), in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma.

Gil efronMichael schicklerChuck padalaExchange commissionCompany contactPurple biotech ltdDrug administrationBristol myers squibbRegulatory affairs of purple biotechDose escalation studyMetastatic squamous cell carcinomaNeck cancerProgress wellPromising signalsEfficacy supporting potential expansionClinical program